Effectiveness of Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children: a Randomized, Double-blind Placebo Controlled Trial

Trial Profile

Effectiveness of Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children: a Randomized, Double-blind Placebo Controlled Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Lactobacillus reuteri (Primary)
  • Indications Diarrhoea
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Nov 2015 Primary endpoint (incidence of nosocomial diarrhoea) has not been met, according to results published in the Pediatric Infectious Disease Journal.
    • 06 Nov 2015 Results published in the Pediatric Infectious Disease Journal
    • 17 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top